tbuckley/cabot-search huggingface dataset:
Caplacizumab: First Global Approval
Authors: Sean Duggan
Journal: Drugs (2018)

Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody® caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval.
FOLFIRINOX therapy for recurrent or unresectable pancreatic cancer
Authors: Masanori Tsujie, Soichi Fumita, Hajime Ishikawa, Kotaro Kitani, Taichi Koyama, Keisuke Inoue, Shuichi Fukuda, Hironobu Manabe, Masao Yukawa, Takao Tamura, Masatoshi Inoue
Journal: Annals of Oncology (2018)
Abstract 19596: Metabolic Remodeling Regulates Cardiac Regeneration in Post-MI Neonatal Mice Heart
Authors: Miikka Tarkia, Susann Björk, Jussi Leinonen, Antti Siltanen, Emil Yliheljo, Maciej Lalowski, Matti Kankainen, Esko Kankuri, Eero Mervaala
Journal: Circulation (2017)

Introduction: The neonatal mouse has a unique regenerative capacity upon myocardial injury during a short time of postnatal development, a capacity that is lost at seven days of age. Previous studi...
Abstract 17039: Aptamer-based Proteomic Profiling Reveals Novel Candidate Biomarkers of Myocardial Injury
Authors: Debby Ngo, Sumita Sinha, Dongxiao Shen, Michelle J Keyes, Xu Shi, John F O’ Sullivan, Laurie Farrell, Michael A Fifer, Marc S Sabatine, Robert E Gerszten
Journal: Circulation (2016)

Background: Emerging proteomic technologies are beginning to permit the systematic characterization of human plasma samples. DNA-aptamer based technologies may address limitations of existing prote...
Ronald Matthew Pollock
Authors: Emma Parkin
Journal: BMJ (2018)

Ronald Matthew Pollock (“Ronnie”) devoted his life to medicine and health planning. A passionate clinician, health strategist, and planner, he spent his long career, which lasted well into his 80s, pursuing the creation of better hospitals and healthcare systems.

He graduated from Selwyn College, Cambridge, and held posts in medicine, surgery, trauma services, and radiotherapy at the Middlesex Hospital in London before becoming a general surgeon in Inverness, Scotland.

Ronnie’s passion for, and skill in, health planning emerged from 1967, when he joined the Oxford regional health authority as a member of the planning team responsible for the development of …
甲氨蝶呤通过 CD73/AMPK/mTOR 通路激活 Treg
Authors: K. Yan, W. Xu, Y. Huang, Z. Zhang, Q. Huang, K.Z. Xin, Y. Ma, L. Han
Journal: British Journal of Dermatology (2018)

银屑病是一种常见的皮肤病, 影响约 2% 至 3% 的人。该病的病因尚不清楚, 被认为涉及基因和免疫系统, 而我们目前采用的治疗仅可控制银屑病, 但无法治愈。这项来自中国的研究旨在了解一种名为甲氨蝶呤的药物对调节性 T 细胞的作用和机制(工作方式),这种细胞具有抵抗和抑制皮肤的能力, 并了解甲氨蝶呤与体内一种称为腺苷的化学物质相关通路的关系,而腺苷是银屑病治疗的靶标。从健康人和银屑病患者的血液中分离出调节性 T 细胞(和可引发牛皮癣的效应 T 细胞)。通过各种实验室检测来检查甲氨蝶呤对腺苷通路的影响。作者发现银屑病患者的调节性 T 细胞功能下降, 这意味着它们不能很好地发挥作用, 并且 CD73 的水平下降,而 CD73 是腺苷通路的起始部分。此外,甲氨蝶呤可通过影响部分腺苷通路恢复调节性 T 细胞的免疫抑制功能,包括增加 CD73 表达并调节其相关信号通路。总之, 该研究加深了医生和患者对甲氨蝶呤治疗银屑病的认识,并有助于我们对银屑病的理解。
Group Purchasing Organizations, Health Care Costs, and Drug Shortages
Authors: William E. Bruhn, Elizabeth A. Fracica, Martin A. Makary
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women
Authors: Po-Hong Liu, Kana Wu, Kimmie Ng, Ann G. Zauber, Long H. Nguyen, Mingyang Song, Xiaosheng He, Charles S. Fuchs, Shuji Ogino, Walter C. Willett, Andrew T. Chan, Edward L. Giovannucci, Yin Cao
Journal: JAMA Oncology (2018)

Colorectal cancer (CRC) incidence and mortality among individuals younger than 50 years (early-onset CRC) are increasing. The reasons for such increases are largely unknown, although the increasing prevalence of obesity may be partially responsible.To investigate prospectively the association between obesity and weight gain since early adulthood with the risk of early-onset CRC.The Nurses' Health Study II is a prospective, ongoing cohort study of US female nurses aged 25 to 42 years at study enrollment (1989). A total of 85 256 women free of cancer and inflammatory bowel disease at enrollment were included in this analysis, with follow-up through December 31, 2011. Validated anthropomorphic measures and lifestyle information were self-reported biennially. Statistical analysis was performed from June 12, 2017, to June 28, 2018.Current body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), BMI at 18 years of age, and weight gain since 18 years of age.Relative risk (RR) for incident early-onset CRC.Among the 85 256 women studied, 114 cases of early-onset CRC were documented (median age at diagnosis, 45 years; interquartile range, 41-47 years) during 1 196 452 person-years of follow-up. Compared with women with a BMI of 18.5 to 22.9, the multivariable RR was 1.37 (95% CI, 0.81-2.30) for overweight women (BMI, 25.0-29.9) and 1.93 (95% CI, 1.15-3.25) for obese women (BMI, ≥30.0). The RR for each 5-unit increment in BMI was 1.20 (95% CI, 1.05-1.38; P = .01 for trend). Similar associations were observed among women without a family history of CRC and without lower endoscopy within the past 10 years. Both BMI at 18 years of age and weight gain since 18 years of age contributed to this observation. Compared with women with a BMI of 18.5 to 20.9 at 18 years of age, the RR of early-onset CRC was 1.32 (95% CI, 0.80-2.16) for women with a BMI of 21.0 to 22.9 and 1.63 (95% CI, 1.01-2.61) for women with a BMI of 23.0 or greater at 18 years of age (P = .66 for trend). Compared with women who had gained less than 5.0 kg or had lost weight, the RR of early-onset CRC was 1.65 (95% CI, 0.96-2.81) for women gaining 20.0 to 39.9 kg and 2.15 (95% CI, 1.01-4.55) for women gaining 40.0 kg or more (P = .007 for trend).Obesity was associated with an increased risk of early-onset CRC among women. Further investigations among men and to elucidate the underlying biological mechanisms are warranted.
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer
Authors: Zebin Wang, Shaun E. Grosskurth, Tony Cheung, Philip Petteruti, Jingwen Zhang, Xin Wang, Wenxian Wang, Farzin Gharahdaghi, Jiaquan Wu, Nancy Su, Ryan T. Howard, Michele Mayo, Dan Widzowski, David A. Scott, Jeffrey W. Johannes, Michelle L. Lamb, Deborah Lawson, Jonathan R. Dry, Paul D. Lyne, Edward W. Tate, Michael Zinda, Keith Mikule, Stephen E. Fawell, Corinne Reimer, Huawei Chen
Journal: Cancer Research (2018)

: PARP proteins represent a class of post-translational modification enzymes with diverse cellular functions. Targeting PARPs has proven to be efficacious clinically, but exploration of the therapeutic potential of PARP inhibition has been limited to targeting poly(ADP-ribose) generating PARP, including PARP1/2/3 and tankyrases. The cancer-related functions of mono(ADP-ribose) generating PARP, including PARP6, remain largely uncharacterized. Here, we report a novel therapeutic strategy targeting PARP6 using the first reported PARP6 inhibitors. By screening a collection of PARP compounds for their ability to induce mitotic defects, we uncovered a robust correlation between PARP6 inhibition and induction of multipolar spindle (MPS) formation, which was phenocopied by PARP6 knockdown. Treatment with AZ0108, a PARP6 inhibitor with a favorable pharmacokinetic profile, potently induced the MPS phenotype, leading to apoptosis in a subset of breast cancer cells in vitro and antitumor effects in vivo. In addition, Chk1 was identified as a specific substrate of PARP6 and was further confirmed by enzymatic assays and by mass spectrometry. Furthermore, when modification of Chk1 was inhibited with AZ0108 in breast cancer cells, we observed marked upregulation of p-S345 Chk1 accompanied by defects in mitotic signaling. Together, these results establish proof-of-concept antitumor efficacy through PARP6 inhibition and highlight a novel function of PARP6 in maintaining centrosome integrity via direct ADP-ribosylation of Chk1 and modulation of its activity. SIGNIFICANCE: These findings describe a new inhibitor of PARP6 and identify a novel function of PARP6 in regulating activation of Chk1 in breast cancer cells.
Non–Small Cell Lung Cancer, Version 1.2015
Authors: David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2014)

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy (RT), which include the following: (1) general principles for early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced/palliative RT; and (3) RT simulation, planning, and delivery. Treatment recommendations should be made by a multidisciplinary team, including board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
Authors: Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai
Journal: Blood (2018)
Recent Advances in Polyesters for Biomedical Imaging
Authors: Mohamed F. Attia, Beau R. Brummel, Timothy R. Lex, Brooke A. Van Horn, Daniel C. Whitehead, Frank Alexis
Journal: Advanced Healthcare Materials (2018)

Abstract Several synthetic materials exhibiting contrast imaging properties have become vital to the field of biomedical imaging. Polymeric biomaterials and metals are commonly used imaging agents and can assist in the monitoring of therapy response, migration, degradation, changes in morphology, defects, and image‐guided surgery. In comparison to metals, most bio and synthetic polymers lack inherent imaging properties. Polymeric biomaterials, specifically polyesters, have gained a considerable amount of attention due to their unique properties including biocompatibility, biodegradation, facile synthesis, and modification capability. Polyester implants and nanomaterials are available on the market or are in clinical trials for many applications including: dental implants, cranio‐maxilofacial implants, soft tissue sutures and staples, abdominal wall repair, tendon and ligament reconstruction, fracture fixation devices, and coronary drug eluting stents. This review aims to provide a summary of the recent developments of polyesters with bioimaging contrast properties. The three main approaches to prepare bioimaging polyesters (coating, encapsulation, and functionalization) are discussed in depth. Furthermore, commonly used imaging modalities including X‐ray computed tomography, magnetic resonance imaging, ultrasound, fluorescence, and radionucleotide polyester contrast agents are highlighted. In each section, examples of impactful bioimaging polyesters in the five major imaging modalities are evaluated.
Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2017–18 School Year
Authors: Jenelle L. Mellerson, Choppell B. Maxwell, Cynthia L. Knighton, Jennifer L. Kriss, Ranee Seither, Carla L. Black
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

State and local school vaccination requirements exist to ensure that students are protected from vaccine-preventable diseases (1). This report summarizes vaccination coverage and exemption estimates collected by state and local immunization programs* for children in kindergarten (kindergartners) in 49 states and the District of Columbia (DC) and kindergartners provisionally enrolled (attending school without complete vaccination or exemption while completing a catch-up vaccination schedule) or in a grace period (a set interval during which a student may be enrolled and attend school without proof of complete vaccination or exemption) for 28 states. Median vaccination coverage† was 95.1% for the state-required number of doses of diphtheria and tetanus toxoids, and acellular pertussis vaccine (DTaP); 94.3% for 2 doses of measles, mumps, and rubella vaccine (MMR); and 93.8% for 2 doses of varicella vaccine. The median percentage of kindergartners with an exemption from at least one vaccine§ was 2.2%, and the median percentage provisionally enrolled or attending school during a grace period was 1.8%. Vaccination coverage among kindergartners remained high; however, schools can improve coverage by following up with students who are provisionally enrolled, in a grace period, or lacking complete documentation of required vaccinations.
What structures are seen by a T cell in the immune response to a lupus autoantigen?
Authors: Robert Winchester
Journal: Annals of the Rheumatic Diseases (2018)

In this decade we have witnessed substantive progress in solving a number of the fundamental enigmas in systemic lupus erythematosus (SLE) that thwart progress towards achieving the goal of inducing disease remission in all patients with this challenging disease. This issue of the Annals of the Rheumatic Diseases contains a paper by Zhao et al 1 , ‘Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification’, which greatly advances understanding of four critical aspects of SLE that are included among these enigmas: Why is the susceptibility to develop SLE associated with the Major Histocompatibility class II allele desinated ﻿ HLA-DR3? What role does the recognition by specific T cell clones of self-peptides presented by HLA-DR3 molecules play in the process of epitope spreading that drives the progressive intensification of a seemingly inconsequential autoimmune response to become a virulent life-threatening autoimmune disease? What roles do the peptides of the diverse commensal and environmental antigens of a person’s environment play in this progressive intensification? Lastly, what events are involved in the transition from asymptomatic autoimmunity to the heterogeneous organ involvement of clinical disease? The paper addresses these questions by analysing in detail the characteristics of both the B cell and T cell immune response to Smith antigen (Sm). It especially focuses on the particular peptides recognised by the clonally specific T cell receptors (TCRs) of the T cell clones proliferating in HLA-DR3 transgenic mice during the response to immunisation by Sm, by elegantly exploiting the property of murine T cells to be readily immortalised as hybridomas.

Several intriguing findings in this paper that address …
Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Authors: Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga
Journal: Clinical Cancer Research (2018)

Abstract Purpose: We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. Experimental Design: ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3. Results: Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations. Conclusions: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.
A phase II study of first-line low-dose afatinib in patients with EGFR mutated non-small-cell lung cancer (KTORG1402)
Authors: Takehiro Okuno, Toshihide Yokoyama, Hiroshige Yoshioka, Daichi Fujimoto, Katsuya Hirano, Takahiro Kawai, Ryogo Kagami, Tadashi Ishida, Keisuke Tomii, Yoshiki Demura, Masataka Hirabayashi, Takashi Nishimura, Yasuharu Nakahara, Young Hak Kim, Kenichi Yoshimura, Toyohiro Hirai
Journal: Annals of Oncology (2018)
Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany
Authors: M. Stecher, A. Chaillon, A.M. Eis-Hübinger, C. Lehmann, G. Fätkenheuer, J.-C. Wasmuth, E. Knops, J.J. Vehreschild, S. Mehta, M. Hoenigl
Journal: Clinical Microbiology and Infection (2018)
CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development
Authors: Emily K. Lehrman, Daniel K. Wilton, Elizabeth Y. Litvina, Christina A. Welsh, Stephen T. Chang, Arnaud Frouin, Alec J. Walker, Molly D. Heller, Hisashi Umemori, Chinfei Chen, Beth Stevens
Journal: Neuron (2018)
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Authors: Sami A Chadi, Lee Malcomson, Joie Ensor, Richard D Riley, Carlos A Vaccaro, Gustavo L Rossi, Ian R Daniels, Neil J Smart, Melanie E Osborne, Geerard L Beets, Monique Maas, Danielle S Bitterman, Kevin Du, Simon Gollins, Arthur Sun Myint, Fraser M Smith, Mark P Saunders, Nigel Scott, Sarah T O'Dwyer, Rodrigo Otavio de Castro Araujo, Marcus Valadao, Alberto Lopes, Cheng-Wen Hsiao, Chien-Liang Lai, Radhika K Smith, Emily Carter Paulson, Ane Appelt, Anders Jakobsen, Steven D Wexner, Angelita Habr-Gama, Guilherme Sao Julião, Rodrigo O Perez, Andrew G Renehan
Journal: The Lancet. Gastroenterology & hepatology (2018)
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
Authors: Pierre-Antoine Juge, Joyce S. Lee, Esther Ebstein, Hiroshi Furukawa, Evgenia Dobrinskikh, Steven Gazal, Caroline Kannengiesser, Sébastien Ottaviani, Shomi Oka, Shigeto Tohma, Naoyuki Tsuchiya, Jorge Rojas-Serrano, Montserrat I. González-Pérez, Mayra Mejía, Ivette Buendía-Roldán, Ramcés Falfán-Valencia, Enrique Ambrocio-Ortiz, Effrosyni Manali, Spyros A. Papiris, Theofanis Karageorgas, Dimitrios Boumpas, Katarina Antoniou, Coline H.M. van Moorsel, Joanne van der Vis, Yaël A. de Man, Jan C. Grutters, Yaping Wang, Raphaël Borie, Lidwine Wemeau-Stervinou, Benoît Wallaert, René-Marc Flipo, Hilario Nunes, Dominique Valeyre, Nathalie Saidenberg-Kermanac’h, Marie-Christophe Boissier, Sylvain Marchand-Adam, Aline Frazier, Pascal Richette, Yannick Allanore, Jean Sibilia, Claire Dromer, Christophe Richez, Thierry Schaeverbeke, Huguette Lioté, Gabriel Thabut, Nadia Nathan, Serge Amselem, Martin Soubrier, Vincent Cottin, Annick Clément, Kevin Deane, Avram D. Walts, Tasha Fingerlin, Aryeh Fischer, Jay H. Ryu, Eric L. Matteson, Timothy B. Niewold, Deborah Assayag, Andrew Gross, Paul Wolters, Marvin I. Schwarz, Michael Holers, Joshua J. Solomon, Tracy Doyle, Ivan O. Rosas, Cornelis Blauwendraat, Mike A. Nalls, Marie-Pierre Debray, Catherine Boileau, Bruno Crestani, David A. Schwartz, Philippe Dieudé
Journal: New England Journal of Medicine (2018)

Given the phenotypic similarities between rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA.
A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study)
Authors: J.-M. Nabholtz, K. Al Saleh, A. Bounedjar, H. Abdel-Razeq, H. Errihani, A. Saadeddin, M. Al Foheidi, M. Ghosn, H. El Zawahry, A. Kandil, N. Abdel-Aziz, F. Dabouz, S. Kullab
Journal: Annals of Oncology (2018)
BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)
Authors: D. Kotani, H. Bando, T. Masuishi, Y. Komatsu, K. Yamaguchi, T.E. Nakajima, T. Satoh, T. Nishina, T. Esaki, S. Nomura, S. Sakamoto, S. Iida, S. Matsuda, M. Yonemura, N. Fuse, A. Sato, S. Fujii, H. Ebi, A. Ohtsu, T. Yoshino
Journal: Annals of Oncology (2018)